Partnership with Maxwell Biotech

Maxwell Biotech is the first independent Russian venture fund focused exclusively on healthcare investments. The fund was created by Maxwell Capital Group, a large diversified financial services organization headquartered in Moscow. The company has created and managed a number of funds in a range of asset classes and risk categories. A team of experts headed by Dmitriy Popov, M.D., manage the fund. The fund is approximately $100 million with 49% of the capital provided by the Russian Venture Company, the Russian federal fund of funds, and the balance from private investors. Maxwell is focused on investments in the areas of pharmaceuticals, biotechnology and agricultural products.

Boston BioCom and Maxwell Biotech have formed a collaboration to support each others’ activities in developing investment opportunities. This alliance stems from the partners’ access to unique Russian technologies further enriched through collaboration with leading US research and clinical organizations and with industry partners. Boston BioCom will provide Maxwell access to its scientific and commercialization expertise as well as source opportunities for US biotech/ pharma companies to utilize the cost effective resources of Russia through entities created by Maxwell. In return, Maxwell will represent an on-the-ground resource for Boston BioCom to source new technologies and assist in the diligent oversight of Boston BioCom funded programs. Maxwell is also in a position to fund very early stage development companies in Russia to advance technology that can then be brought into the Boston BioCom portfolio.

link: http://www.maxwell.ru/english.aspx

back to Our Partners